1. Disclaimer
This monograph is provided for professional and educational informational purposes only and is not a substitute for the current approved product information, professional clinical judgment, or advice from a qualified healthcare professional. Product composition, indications, warnings, regulatory status, and other information may change; the current official product labeling and applicable Egyptian regulatory sources should always be consulted.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
This information should not be used for self-medication, diagnosis, treatment selection, dose adjustment, or emergency management. The current approved leaflet and prescribing information should take precedence whenever available.
2. Summary
EPICOPHYLLINE® Syrup is an oral respiratory preparation historically described as a bronchodilator containing acefylline piperazine. However, currently available Egyptian market databases identify EPICOPHYLLINE 2.5 g/100 ml syrup 125 ml as containing acefylline piperazine + phenobarbital, while an older Egyptian registered-product record lists the same EPICOPHYLLINE 2.5 g/100 ml presentation as acefylline piperazine alone. Therefore, the exact current composition of a particular marketed pack should be verified against the current approved package leaflet and the labeled composition before use.
The separate product name EPICOPHYLLINE PHENOBARBITONE syrup 125 ml is consistently identified in available Egyptian market records as an acefylline piperazine + phenobarbital/phenobarbitone combination.
The Egyptian Drug Authority has issued a specific safety communication concerning acefylline piperazine + phenobarbital/phenobarbitone combinations, citing drug interactions, dependence, and numerous adverse effects associated with phenobarbital.
Acefylline piperazine is a xanthine-related bronchodilator. Its role should be interpreted in the context of current asthma standards. GINA 2026 does not recommend oral theophylline because of lower efficacy and greater adverse-effect risk than inhaled bronchodilator therapy; this does not establish complete pharmacological equivalence between acefylline piperazine and theophylline.
3. Brand Name
EPICOPHYLLINE® Syrup
Available Egyptian market records identify:
EPICOPHYLLINE 2.5g/100ml syrup 125 ml
with EIPICO as the producer and, in current market databases, with Acefylline piperazine + Phenobarbital listed as the active-ingredient combination.
A separate product is listed as:
EPICOPHYLLINE PHENOBARBITONE syrup 125 ml
and is identified as Acefylline piperazine + Phenobarbital/Phenobarbitone.
Because historical Egyptian registration records show a different composition for the EPICOPHYLLINE 2.5 g/100 ml presentation, the exact composition of the current pack should be confirmed from its current approved labeling.
4. Category
Pharmacological category: Bronchodilator
Therapeutic group: Other systemic drugs for obstructive airway diseases; xanthine derivative.
ATC classification: R03DA09 — Acefylline piperazine.
Where phenobarbital is present, the product additionally contains a barbiturate central nervous system depressant.
5. Active Ingredient
The currently available Egyptian market databases identify EPICOPHYLLINE 2.5g/100ml syrup 125 ml as containing:
- Acefylline piperazine
- Phenobarbital (Phenobarbitone)
The separate EPICOPHYLLINE PHENOBARBITONE product is likewise identified as containing acefylline piperazine + phenobarbital/phenobarbitone.
An exact current concentration of phenobarbital in the 2.5 g/100 ml EPICOPHYLLINE presentation was not independently verified from an authoritative current product leaflet and is therefore not stated here.
6. Pharmaceutical Form & Strength
Pharmaceutical form: Oral syrup.
Presentation identified in Egyptian market records:
125 ml bottle
Acefylline piperazine strength:
The product name and historical product information identify 2.5 g/100 ml.
This is equivalent to:
25 mg/ml acefylline piperazine.
Phenobarbital:
Current Egyptian market databases identify phenobarbital as part of the active-ingredient combination, but a reliable current source establishing its exact concentration in this specific 2.5 g/100 ml presentation was not independently verified.
7. Manufacturer & Marketing Authorization Holder
Manufacturer / Product Company:
Egyptian International Pharmaceutical Industries Company (EIPICO)
10th of Ramadan City, Egypt.
Available Egyptian market records identify EIPICO as the producer of EPICOPHYLLINE.
Marketing Authorization Holder:
EIPICO is identified as the Egyptian manufacturer/product company. A separate current public regulatory record explicitly identifying a different marketing authorization holder was not independently verified.
8. Mechanism of Action
Acefylline piperazine
Acefylline is a theophylline-related xanthine derivative with bronchodilator activity.
Experimental pharmacology has demonstrated inhibition of lung cyclic-AMP phosphodiesterase activity, while acefylline and related compounds also exhibit activity at adenosine receptors. The exact mechanism responsible for the clinical bronchodilator effect of acefylline piperazine is not completely established.
The resulting pharmacological effect is relaxation of bronchial smooth muscle and reduction of bronchospasm.
Phenobarbital
Where present, phenobarbital is a barbiturate that enhances inhibitory GABA-A-mediated neurotransmission and produces central nervous system depression. The Egyptian Drug Authority identifies phenobarbital as a sedative-hypnotic barbiturate and describes its action through enhancement of GABA-A receptor-mediated chloride-channel activity.
Phenobarbital does not provide the bronchodilator mechanism of acefylline piperazine.
9. Spectrum of Activity
Not applicable in the antimicrobial sense.
EPICOPHYLLINE is not an antibiotic and has no antibacterial, antiviral, antifungal, or antiparasitic spectrum of activity.
Its principal respiratory pharmacological action is bronchodilation through the acefylline piperazine component.
If phenobarbital is present, it contributes a CNS depressant/barbiturate effect rather than an antimicrobial or bronchodilator spectrum.
10. Pharmacokinetics
Reliable, contemporary human pharmacokinetic data specifically characterizing acefylline piperazine as marketed in EPICOPHYLLINE syrup are limited in readily accessible authoritative sources.
Acefylline piperazine should therefore not automatically be assigned the pharmacokinetic parameters of theophylline. Published resources describe acefylline as a xanthine-related compound, but a complete current product-specific human pharmacokinetic profile was not independently verified.
Accordingly, numerical values for absorption rate, bioavailability, distribution volume, half-life, metabolism, and clearance are not presented here as established product-specific facts.
Phenobarbital
Phenobarbital is absorbed systemically and undergoes hepatic metabolism and renal elimination. It has a relatively long duration of action and can induce hepatic cytochrome P450 enzymes, resulting in clinically important interactions with other medicines. The Egyptian Drug Authority specifically highlights its hepatic enzyme-inducing effect.
Product-specific pharmacokinetic parameters for the EPICOPHYLLINE syrup combination were not independently verified and are therefore not provided.
11. Indications
Historically, acefylline piperazine products have been used as systemic bronchodilators in respiratory disorders associated with bronchospasm, including:
- Bronchial asthma.
- Bronchospastic respiratory conditions.
- Chronic bronchitis associated with bronchospasm.
- Emphysema-associated bronchospasm.
Older product descriptions also mentioned dyspnoea and use across different age groups; however, dyspnoea is a symptom rather than a specific diagnosis, and its cause should be established before treatment.
Some current Egyptian market references list EPICOPHYLLINE for bronchial asthma and respiratory conditions, including chronic bronchitis and emphysema.
EPICOPHYLLINE should not be represented as a preferred contemporary treatment for acute asthma exacerbation. Current asthma management favors inhaled, evidence-based therapies, and oral theophylline is not recommended in contemporary GINA strategy because of limited efficacy and adverse-effect concerns.
12. Administration
Route: Oral.
The syrup should be administered using an accurate measuring device.
The prescribed quantity and frequency should be determined from the current approved product information or an appropriate healthcare professional, rather than relying on historical dosing statements.
This is particularly important because phenobarbital-containing formulations carry additional CNS-depressant, dependence, withdrawal, and drug-interaction considerations. The Egyptian Drug Authority states that abrupt discontinuation of phenobarbital after prolonged use may cause withdrawal symptoms and that tapering may be necessary.
13. Method of Preparation
EPICOPHYLLINE is supplied as a ready-to-use oral syrup.
No reconstitution step with water is required unless the current package leaflet specifically instructs otherwise.
The bottle should be handled according to the manufacturer's current instructions. Shake before administration when required by the product labeling.
14. Contraindications
The product should not be used in patients with a known hypersensitivity to acefylline piperazine, phenobarbital, or any component of the formulation, where these ingredients are present.
Because phenobarbital may cause significant CNS and respiratory depression, particular caution and professional assessment are required in patients with significant respiratory depression or other conditions in which CNS depressant effects could be hazardous.
A complete, current product-specific contraindication list could not be independently verified from a current official public leaflet; therefore, additional contraindications are not added speculatively.
15. Warnings & Precautions
EPICOPHYLLINE should be used only under appropriate professional supervision.
Particular caution is appropriate in patients with significant cardiovascular disease, arrhythmias, hepatic or renal impairment, seizure disorders, or marked sensitivity to xanthine-related stimulant effects.
Where phenobarbital is present, additional precautions are required because of:
- CNS depression and sedation.
- Possible respiratory depression.
- Hypotension and bradycardia.
- Dependence with prolonged use.
- Withdrawal symptoms after abrupt discontinuation.
- Hepatic enzyme induction and clinically important drug interactions.
- Rare but severe dermatological reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
These risks are specifically described by the Egyptian Drug Authority for acefylline piperazine + phenobarbital/phenobarbitone combinations.
The preparation should not be used for unexplained dyspnoea without medical assessment, because dyspnoea may result from conditions requiring urgent or specific treatment.
16. Drug Interactions
Phenobarbital, when present, is a potent hepatic enzyme inducer and may reduce the effectiveness of numerous medicines metabolized by hepatic cytochrome P450 pathways. The Egyptian Drug Authority specifically warns that careful consideration is required when phenobarbital is administered with other medicines.
Concomitant use with other sedatives, hypnotics, CNS depressants, or medicines that impair respiratory function may increase CNS and respiratory depression.
Because acefylline is a xanthine-related bronchodilator, concomitant use with other methylxanthine-containing medicines should also be assessed carefully.
Patients should provide a complete list of prescription medicines, non-prescription medicines, and other respiratory preparations to the prescriber or pharmacist before use.
17. Side Effects
Potential adverse effects related to the acefylline/xanthine component may include:
- Nausea, vomiting, abdominal discomfort, or other gastrointestinal upset.
- Headache or dizziness.
- Nervousness, restlessness, insomnia, or tremor.
- Palpitations or other cardiovascular symptoms.
Where phenobarbital is present, additional adverse effects can include:
- Drowsiness or somnolence.
- Dizziness, impaired balance, or ataxia.
- Confusion and CNS depression.
- Nausea, vomiting, or constipation.
- Hypotension, bradycardia, or syncope.
- Respiratory depression, hypoventilation, or apnea.
- Hypersensitivity reactions and skin rash.
- Rare severe cutaneous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
- Liver injury.
- Withdrawal symptoms after abrupt cessation following prolonged use.
The Egyptian Drug Authority specifically reports these phenobarbital-associated risks for acefylline piperazine + phenobarbital/phenobarbitone combinations.
18. Use in Special Populations
Children and infants:
Historical EPICOPHYLLINE literature described pediatric use, including infants; however, a current authoritative product-specific pediatric dosage regimen was not independently verified.
If the current formulation contains phenobarbital, additional pediatric caution is necessary because of its CNS-depressant and respiratory effects.
Elderly:
Use should be individualized because older patients may have increased susceptibility to adverse CNS and cardiovascular effects and may be receiving multiple concomitant medicines.
Pregnancy:
Current product-specific human pregnancy safety information sufficient to establish safety was not independently verified. Use should therefore be based on an individualized risk-benefit assessment by the treating clinician.
Breastfeeding:
Current product-specific data sufficient to establish safety during lactation were not independently verified. Professional assessment is recommended before use.
Renal or hepatic impairment:
A current product-specific dose-adjustment schedule was not independently verified. Such patients require professional assessment before treatment.
19. Storage Conditions
A current product-specific storage temperature stated in an official publicly accessible EIPICO leaflet was not independently verified.
Therefore:
Store according to the storage instructions printed on the current package and approved leaflet.
Keep the medicine out of the reach of children and protect it from inappropriate storage conditions such as excessive heat or direct sunlight.
20. Additional Sections
Formulation Identification
A significant formulation-identification issue applies to the EPICOPHYLLINE name in Egyptian drug records.
Current Egyptian market databases identify:
EPICOPHYLLINE 2.5g/100ml syrup 125 ml
— Acefylline piperazine + Phenobarbital.
They also identify:
EPICOPHYLLINE PHENOBARBITONE syrup 125 ml
— Acefylline piperazine + Phenobarbital/Phenobarbitone.
However, an older Egyptian registered-product record lists:
EPICOPHYLLINE 2.5g/100ml syrup 125 ml
— Acefylline piperazine,
while separately listing EPICOPHYLLINE PHENOBARBITONE as acefylline piperazine + phenobarbital.
Consequently, the current package labeling should be considered the decisive source for the exact composition of an individual marketed pack, especially because the available records are not fully consistent.
Egyptian Regulatory Safety Information
The Egyptian Drug Authority issued a September 2023 Direct Healthcare Professional Communication specifically concerning:
Acefylline Piperazine + Phenobarbital / Acefylline Piperazine + Phenobarbitone
The communication warns of drug interactions, dependence, and multiple adverse effects associated with phenobarbital/phenobarbitone, including CNS depression, respiratory depression, hypotension, bradycardia, sedation, withdrawal symptoms, and serious dermatological reactions.
The Egyptian Drug Authority's Technical Committee also recorded decisions concerning products containing acefylline piperazine + phenobarbital, citing the absence of a scientific basis for phenobarbital in the treatment of asthma/chronic cough and safety concerns associated with the combination.
Contemporary Therapeutic Context
Modern asthma management favors inhaled therapies with established efficacy and safety profiles. Oral methylxanthine therapy has a limited role in contemporary asthma practice because of its relatively narrow therapeutic margin and adverse-effect burden.
Accordingly, EPICOPHYLLINE should not be described as a first-line contemporary asthma treatment solely on the basis of its historical bronchodilator indication.
21. Frequently Asked Questions (FAQ)
What is EPICOPHYLLINE?
EPICOPHYLLINE is an oral respiratory preparation historically used as a bronchodilator and associated with acefylline piperazine.
What is the strength of EPICOPHYLLINE syrup?
The presentation is identified as 2.5 g/100 ml and 125 ml in Egyptian market records. Current market databases identify the formulation as acefylline piperazine + phenobarbital, but the exact phenobarbital concentration was not independently verified.
Is EPICOPHYLLINE an antibiotic?
No. It is a respiratory preparation with bronchodilator pharmacology and does not have an antibacterial, antiviral, antifungal, or antiparasitic spectrum.
Does EPICOPHYLLINE contain phenobarbital?
Current Egyptian market databases identify EPICOPHYLLINE 2.5g/100ml syrup 125 ml as containing acefylline piperazine + phenobarbital.
There is, however, an older Egyptian registered-product record in which the same EPICOPHYLLINE 2.5g/100ml presentation is listed as acefylline piperazine alone.
Therefore, the current approved composition printed on the actual package/leaflet should be checked for the specific marketed pack.
Is EPICOPHYLLINE PHENOBARBITONE the same product?
It is a separate product name, but available Egyptian records identify both EPICOPHYLLINE PHENOBARBITONE and the currently listed EPICOPHYLLINE 2.5g/100ml presentation as containing the combination of acefylline piperazine + phenobarbital/phenobarbitone.
Can the older tablespoon-based dosing instructions be used?
They should not be treated as current authoritative dosing instructions. A current approved product leaflet or professional prescription should be followed.Can EPICOPHYLLINE be used for unexplained shortness of breath?
No medicine should be used to self-treat unexplained dyspnoea. The underlying cause should first be assessed because shortness of breath may indicate asthma, COPD, cardiac disease, infection, pulmonary embolism, or other potentially serious conditions.
What are the important concerns if phenobarbital is present?
The Egyptian Drug Authority warns about dependence, drug interactions, CNS depression, respiratory depression, hypotension, bradycardia, sedation, and withdrawal following abrupt discontinuation of phenobarbital-containing acefylline combinations.
22. References
- Egyptian Drug Authority — Technical Committee Decisions, 2023: regulatory decisions concerning products containing Acefylline piperazine + phenobarbital/phenobarbitone and associated scientific/safety considerations.
- Egyptian Drug Authority — Direct Healthcare Professional Communication, September 2023: Acefylline Piperazine + Phenobarbital / Phenobarbitone; risks of drug interaction, dependence, and multiple adverse effects with long-term use.
- Egyptian market drug database — EPICOPHYLLINE 2.5g/100ml syrup 125 ml: current listing identifying Acefylline Piperazine + Phenobarbital and EIPICO as manufacturer.
- Egyptian market drug database — EPICOPHYLLINE PHENOBARBITONE syrup 125 ml: listing identifying Acefylline piperazine + phenobarbital/phenobarbitone and EIPICO as manufacturer.
- Historical Egyptian registered-product record: EPICOPHYLLINE 2.5g/100ml syrup listed as Acefylline piperazine, with EPICOPHYLLINE PHENOBARBITONE separately listed as Acefylline piperazine + Phenobarbital.
- NCATS / National Center for Advancing Translational Sciences: pharmacological information concerning acefylline piperazine.
- PubMed: pharmacological investigation of acefylline/theophylline-7-acetic acid and phosphodiesterase-related bronchodilator activity.
- Current asthma treatment guidance: GINA 2026, concerning the limited role and safety concerns of oral theophylline/xanthine-related therapy.